Pharmaceutical company Lupin Ltd announced on Friday the launch of its Ipratropium Bromide nasal spray in the United States, used primarily for treating runny nose symptoms.
In a regulatory filing, the company stated that the nasal spray is available in two strengths — 0.03% and 0.06%. Both formulations are bioequivalent to Atrovent nasal spray, developed by Boehringer Ingelheim Pharmaceuticals, Inc., in the same strengths.
The 0.03% Ipratropium Bromide nasal spray is approved for symptomatic relief of rhinorrhea (runny nose) associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older.
Meanwhile, the 0.06% version is indicated for relief from rhinorrhea related to the common cold or seasonal allergic rhinitis in adults and children aged 5 years and above.
Citing IQVIA MAT data from May 2025, Lupin noted that the U.S. market for Ipratropium Bromide nasal solution (branded as Atrovent) had an estimated annual sales value of USD 63 million.